Lunaphore and CRO Sirona Dx Collaborate to Expand COMET™ Offerings to US-based Biotech and Biopharma Customers
23.2.2023 19:00:00 EET | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. COMET™ will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005618/en/
Lunaphore’s COMET™ platform is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible. Thanks to its versatility, COMET™ has a wide range of research applications across multiple disciplines and all stages of research and drug development.
Sirona Dx is a highly-specialized technical CRO and pioneer of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic service capabilities contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“Platform selection is one of the most important decisions to make when developing multiplexed tissue imaging panels for our clients”, said Andrew Brown, Ph.D., Chief Commercial Officer at Sirona Dx. “We are extremely pleased to partner with Lunaphore to integrate the COMET™ platform into our spatial-omics operations. The ability to select off-the-shelf, label-free primary antibodies is highly advantageous and reduces the time required to develop robust, highly reproducible assays.
“The deployment of COMET™ at Sirona Dx is particularly meaningful for Lunaphore as it helps to address the large demand from US-based biotech and biopharmaceutical companies to access highly reproducible hyperplex data,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “Furthermore, Sirona Dx’s CLIA certification and deep understanding of pharmaceutical regulatory requirements add significant value for scientists looking to adopt spatial biology tools to accelerate translational research”.
To learn more about the COMET™ platform, please visit:
https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology with an intuitive approach. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit: www.lunaphore.com
About COMET™
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of 40 different spatial markers per automated run on a tissue slide. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About Sirona Dx
Sirona Dx is a technical CRO, founded in 2016 to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research, Sirona Dx offers specialized high complexity, single-cell services supporting exploratory biomarker programs and advanced precision medicine initiatives to deliver safer and more effective treatment solutions. Learn more at Sironadx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005618/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Andrew Brown, PhD
Chief Commercial Officer, Sirona Dx
Email: abrown@sironadx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Introduces NXP-based FCM365X Wi-Fi 6, Bluetooth LE 5.4, Zigbee and Thread Module for Smart Home and Industrial IoT Solutions24.6.2026 11:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FCM365X, a dual band Wi-Fi 6 and Bluetooth Low Energy (BLE) 5.4 module that is based on the NXP® Semiconductors RW612 wireless MCU and supports multiple protocols, including Zigbee and Thread. The module is powered by a high-performance Arm® Cortex®-M33 processor with TrustZone® technology, operating at up to 260MHz. It integrates 1.2MB of SRAM and 8MB of Flash memory, with optional PSRAM expansion available, delivering the performance and memory capacity required for demanding IoT applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624781458/en/ Quectel introduces NXP-based FCM365X Wi-Fi 6, Bluetooth LE 5.4, Zigbee and Thread module for smart home and industrial IoT solutions As smart home and industrial IoT ecosystems continue to evolve, support for interoperable standards such as Thread and Zigbee is becom
Boomi Announces Its FY26 EMEA Customer Innovation Award Winners24.6.2026 11:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced the EMEA winners of its FY26 Boomi Customer Innovation Awards, at Boomi World Tour London, taking place 23–24 June 2026 at the Park Plaza Westminster Bridge, London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624407145/en/ Boomi Announces Its FY26 EMEA Customer Innovation Award Winners Across Europe, the Middle East and Africa, a new generation of organisations is redefining what it means to be a data-driven business. This year's EMEA Customer Innovation Award winners have done more than implement technology, they have fundamentally changed how their organisations operate, compete, and grow. Working with the Boomi Enterprise Platform, they have turned fragmented data into strategic advantage, replaced manual complexity with intelligent automation, and in many cases laid the groundwork for enterprises built to move faster, decide smarter, and act with confidenc
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO24.6.2026 10:05:00 EEST | Press release
In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda’s Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Directors appointed her as Representative Director, President & CEO. Upon conclusion of the meeting, former president & CEO Christophe Weber retired from the Company and the Board. Chair of the Board of Directors Meeting, Masami Iijima, commented: “On behalf of Takeda’s Board of Directors, I would like to congratulate Julie Kim on becoming Takeda’s President and CEO. The Board of Directors is confident in Ms. Kim to drive executional excellence as Takeda launches a number of highly anticipated medicines and grows long-term shareholder value. The Board
Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds24.6.2026 09:30:00 EEST | Press release
AI transparency has become a commercial differentiator, and it's reshaping where brand revenue is won — or lost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623804294/en/ Over half (52%) of consumers globally will pay more for brands that are transparent about how they use AI with their data at an average 7% premium. In Germany, that figure rises to 73% of consumers willing to pay a 9% premium, the highest of any market. The finding comes from the second annual State of Digital Trust 2026 Report, commissioned by Usercentrics, a leading data privacy technology company, and conducted by Sapio Research across 11,000 consumers in seven markets. The opportunity for brands that act is matched by the cost of inaction. Almost half (47%) of consumers surveyed have taken at least one action with a direct revenue consequence in the past six months because of concerns about how their data was being used in AI — canceling a subscri
LTM Joins Athena, a Chainguard-led Industry Coalition to Help Secure Open Source Software in the AI Era24.6.2026 09:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has joined Athena, a new industry coalition led by Chainguard, focused on protecting open source software from the rising threat of AI-driven vulnerabilities. Athena brings together leading organizations across the global software ecosystem to address an urgent challenge. As frontier AI models advance, they are increasingly capable of identifying novel vulnerabilities in open source software at machine speed, often faster than traditional disclosure and patching processes can respond. As AI accelerates both software development and the discovery of vulnerabilities, the window between a flaw being identified and being exploited has narrowed sharply. Athena is designed to close this gap through shared intelligence, coordinated action, and pre-disclosure remediation across the ecosystem. The coalition supports vulnerability management end to end, from discovery and analysis to patching, layered mitigations, and upstr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom